Medtide Inc is a China-based company mainly engaged in the contract research, development and manufacturing of peptide. The Company mainly provides contract research organization (CRO) services, namely peptide new chemical entity (NCE) discovery synthesis, contract development and manufacturing organization (CDMO) services, namely peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. The Company's services primarily focus on providing customers with active pharmaceutical ingredients (APIs) rather than drug products. The Company also provides customers with peptide drug development, production, and CMC filing support services. The Company mainly operates its business in the domestic market and overseas markets.

Employees

596

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
22/09/26	HK$20.88	+4.56%	90,300
21/09/26	HK$19.97	-3.15%	91,600
18/09/26	HK$20.62	+6.51%	149,300
17/09/26	HK$19.36	+0.94%	81,600
16/09/26	HK$19.18	+1.32%	165,400

Delayed Quote Hong Kong S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

17.84CNY

Average target price

19.66CNY

Spread / Average Target

+10.26%

Consensus

Net sales - Rate of surprise

Company calendar

Market Closed - Hong Kong S.E. 09:08:13 22/09/2026 BST			5-day change	1st Jan Change
20.88 ^HKD	+4.56%		+10.71%	-31.50%

08-27	Medtide Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-31	Medtide Names CFO	MT

Market Cap	2.53B 2.96B 377M 330M 310M 283M 531M 36.09B 531M 3.72B 1.44B 18.43B 1.42B 1.39B 59.41B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	1.95B 2.28B 291M 254M 239M 218M 409M 27.82B 410M 2.87B 1.11B 14.21B 1.09B 1.07B 45.81B	EV / Sales 2026 *	3.26x	EV / Sales 2027 *	2.53x
Free-Float	19.48%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Hong Kong S.E.	3880	Delayed
Deutsche Boerse AG	FQ2	Delayed

08-27	Medtide Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-31	Medtide Names CFO	MT
07-31	Medtide Inc. Announces Appointment of Ding Lijun as Chief Financial Officer, Effective July 31, 2026	CI
07-31	Medtide Inc. Announces Management Changes, Effective July 31, 2026	CI
07-31	Medtide Inc. Announces Change of Principal Place of Business in Hong Kong	CI
07-31	Medtide Inc. Provides Group Earnings Guidance for the Six Months Ended Year Ended June 30, 2026	CI
06-30	95,524,875 H Shares of Medtide Inc. are subject to a Lock-Up Agreement Ending on 29-JUN-2026.	CI
06-18	Medtide Inc. Announces Abolishment of the Supervisory Committee	CI
03-30	Medtide Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-09	Medtide Completes Hong Kong-Listed Share Full Circulation	MT
02-26	Medtide Forecasts Higher 2025 Profit on Back of Up to 32% Rise in Revenue	MT
02-25	Medtide Inc. Provides Preliminary Group Earnings Guidance for the Year Ended December 31, 2025	CI
02-06	Medtide Gets CSRC Nod for Hong Kong Share Full Circulation	MT

Medtide Inc. Share Price

Stocks

3880

CNE100006S86

Biotechnology & Medical Research

Valuation: Medtide Inc.

Chart: Medtide Inc.

Latest news: Medtide Inc.

Press Releases: Medtide Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Medtide Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Net sales - Rate of surprise

1 day	+4.56%
1 week	+10.71%
Current month	-5.86%
1 month	-10.54%
3 months	-7.28%
6 months	-4.22%
Current year	-31.50%

1 week	18.42	21.3
1 month	17.64	23.6
Current year	17.64	30.46
1 year	17.64	33.18
3 years	17.64	41.72
5 years	17.64	41.72
10 years	17.64	41.72

Manager	Title	Age	Since
Qi Xu CEO	Chief Executive Officer	58	10/06/2020
Li Jun Ding DFI	Director of Finance/CFO	50	30/07/2026
Wei Qun Xu DFI	Director of Finance/CFO	53	30/09/2020

Director	Title	Age	Since
Qi Xu CHM	Chairman	58	10/06/2020
Xiang Li Li BRD	Director/Board Member	51	26/01/2022
Xiang Li BRD	Director/Board Member	63	26/01/2022

Date	Insider	Type	Main position	Quantity	% Market Cap.
09/03/26	Qi Xu	Other	Chief Executive Officer	68,201,112	48.0967%
09/03/26	Xiang Li Li	Other	Director	68,201,112	48.0967%
09/03/26	Qi Xu	Other	Chief Executive Officer	68,201,112	48.0967%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MEDTIDE INC.	+4.56%	+10.71%	-31.76%	-	361M
LONZA GROUP AG	+2.55%	+5.35%	+3.61%	+32.02%	46.68B
IQVIA HOLDINGS INC.	+0.08%	+0.16%	+43.79%	+35.89%	44.42B
REVOLUTION MEDICINES, INC.	+0.05%	-5.86%	+334.27%	+542.87%	41.32B
BEONE MEDICINES AG	+0.66%	+6.23%	+8.96%	+93.14%	41.58B
CELLTRION, INC.	-1.60%	-0.17%	+9.73%	+43.63%	30.14B
MEDPACE HOLDINGS, INC.	+0.96%	+1.56%	+26.52%	+159.67%	17.42B
ASCENDIS PHARMA A/S	-0.01%	-0.92%	-	-	15.6B
EUROFINS SCIENTIFIC SE	+1.15%	+7.46%	+25.97%	+43.93%	15.54B
TEMPUS AI, INC.	-1.08%	+12.11%	-10.11%	-	14.08B
Average	+0.76%	+3.64%	+45.67%	+135.88%	26.71B
Weighted average by Cap.	+0.48%	+1.95%	+68.79%	+144.12%

	2026 *	2027 *
Net sales	599M 701M 89.34M 78.07M 73.38M 66.96M 126M 8.54B 126M 881M 340M 4.36B 336M 328M 14.06B	742M 869M 111M 96.81M 90.99M 83.03M 156M 10.59B 156M 1.09B 421M 5.41B 416M 407M 17.44B
Net income	-	-
Net Debt	-579M -678M -86.41M -75.51M -70.97M -64.77M -122M -8.26B -122M -852M -329M -4.22B -324M -317M -13.6B	-649M -760M -96.86M -84.65M -79.56M -72.6M -136M -9.26B -136M -955M -368M -4.73B -364M -356M -15.24B